Home › Research › Disease mechanisms
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle
Jae-Eun Kang, Miranda M. Lim, Randall John Bateman, James J. Lee, Liam P. Smyth, John R. Cirrito, Nobuhiro Fujiki, Seiji Nishino, David M. Holtzman. Science, 2009-09-25
Topic: Brain proteins, microglia and lab models
Amyloid-beta (Abeta) accumulation in the brain extracellular space is a hallmark of Alzheimer's disease. The factors regulating this process are only partly understood. Abeta aggregation is a concentration-dependent process that is likely responsive to changes in brain interstitial fluid (ISF) levels of Abeta. Using in vivo microdialysis in mice, we found that the amount of ISF Abeta correlated with wakefulness. The amount of ISF Abeta also significantly increased during acute sleep deprivation and during orexin infusion, but decreased with infusion of a dual orexin receptor antagonist. Chronic sleep restriction significantly increased, and a dual orexin receptor antagonist decreased, Abeta plaque formation in amyloid precursor protein transgenic mice. Thus, the sleep-wake cycle and orexin may play a role in the pathogenesis of Alzheimer's disease.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kang, J.-E., Lim, M. M., Bateman, R. J., Lee, J. J., Smyth, L. P., Cirrito, J. R., et al. (2009). Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science. https://doi.org/10.1126/science.1180962
Vancouver
Kang J.-E, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science. 2009. doi:10.1126/science.1180962. PMID: 19779148.
BibTeX
@article{kang2009-19779148,
author = {Kang, Jae-Eun and Lim, Miranda M. and Bateman, Randall John and Lee, James J. and Smyth, Liam P. and Cirrito, John R. and Fujiki, Nobuhiro and Nishino, Seiji and Holtzman, David M.},
title = {{Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle}},
journal = {Science},
year = {2009},
doi = {10.1126/science.1180962},
pmid = {19779148},
url = {https://doi.org/10.1126/science.1180962}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 9 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Why it matters
In mice, amyloid-beta levels in brain fluid rose with wakefulness, acute sleep deprivation and orexin infusion, and fell with a drug that blocks orexin receptors. Chronic sleep restriction increased amyloid plaque formation in mice engineered to make amyloid precursor protein, and the authors suggest the sleep-wake cycle and orexin may play a role in Alzheimer's disease.
How this study scored 62/100
Published in a top-tier journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 59 of the 95 points we could judge it on, which is 62 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Science) |
| Journal's citation record | 4 / 4 | Science: journal h-index 1,754 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | — / 5 | No evidence rating recorded — left out of this score |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2009 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,563 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 82.3 citations a year over 19 year(s) since 2009 |
| Impact for its field and year | 5 / 6 | Cited 24.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 4 / 4 | Cited 344 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author David M. Holtzman: h-index 206 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Stanford University: institution h-index 2,684 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19779148) |
| Free to read | 2 / 2 | Free to read |
| Points | 59 / 95 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 95 points we could judge it on is 62 out of 100. |
| Total | 62 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related studies in Disease mechanisms
Also tagged “precursor”
1,339 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,339 tagged studies.